NO330903B1 - Nukleinsyrer, anti-IL-12-antistoff, sammensetning inneholdende denne samt vertscelle. - Google Patents

Nukleinsyrer, anti-IL-12-antistoff, sammensetning inneholdende denne samt vertscelle. Download PDF

Info

Publication number: NO330903B1
Authority: NO; Norway
Prior art keywords: antibody; human; antibodies; cells; agent
Prior art date: 2000-08-07

Application number

NO20030614A

Other languages

English (en)

Norwegian (no)

Other versions

NO20030614D0 (no

NO20030614L (no

Inventor

Jill Giles-Komar

David M Knight

David Peritt

Bernard Scallon

David Shealy

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-07

Filing date

2003-02-07

Publication date

2011-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO330903(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-07 Application filed by Centocor Inc filed Critical Centocor Inc

2003-02-07 Publication of NO20030614D0 publication Critical patent/NO20030614D0/no

2003-04-02 Publication of NO20030614L publication Critical patent/NO20030614L/no

2011-08-15 Publication of NO330903B1 publication Critical patent/NO330903B1/no

Links

239000000203 mixture Substances 0.000 title claims description 82
150000007523 nucleic acids Chemical class 0.000 title claims description 62
102000039446 nucleic acids Human genes 0.000 title claims description 59
108020004707 nucleic acids Proteins 0.000 title claims description 59
241000282414 Homo sapiens Species 0.000 claims description 130
239000003085 diluting agent Substances 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 25
239000003937 drug carrier Substances 0.000 claims description 4
201000000306 sarcoidosis Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
238000003745 diagnosis Methods 0.000 claims description 3
230000007170 pathology Effects 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 156
102000013462 Interleukin-12 Human genes 0.000 description 146
108010065805 Interleukin-12 Proteins 0.000 description 146
229940117681 interleukin-12 Drugs 0.000 description 141
238000000034 method Methods 0.000 description 110
108090000623 proteins and genes Proteins 0.000 description 92
239000012634 fragment Substances 0.000 description 68
235000018102 proteins Nutrition 0.000 description 68
102000004169 proteins and genes Human genes 0.000 description 68
230000027455 binding Effects 0.000 description 56
239000000243 solution Substances 0.000 description 56
235000001014 amino acid Nutrition 0.000 description 50
229940024606 amino acid Drugs 0.000 description 44
150000001413 amino acids Chemical class 0.000 description 44
108020004414 DNA Proteins 0.000 description 40
238000002360 preparation method Methods 0.000 description 38
239000000427 antigen Substances 0.000 description 37
108091007433 antigens Proteins 0.000 description 37
102000036639 antigens Human genes 0.000 description 37
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 36
102100040247 Tumor necrosis factor Human genes 0.000 description 33
239000003795 chemical substances by application Substances 0.000 description 33
-1 rDNA Proteins 0.000 description 32
239000000872 buffer Substances 0.000 description 29
235000014113 dietary fatty acids Nutrition 0.000 description 29
229930195729 fatty acid Natural products 0.000 description 29
239000000194 fatty acid Substances 0.000 description 29
102000040430 polynucleotide Human genes 0.000 description 28
108091033319 polynucleotide Proteins 0.000 description 28
239000002157 polynucleotide Substances 0.000 description 28
230000000694 effects Effects 0.000 description 26
108090000765 processed proteins & peptides Proteins 0.000 description 26
230000014509 gene expression Effects 0.000 description 25
102000000588 Interleukin-2 Human genes 0.000 description 24
108010002350 Interleukin-2 Proteins 0.000 description 24
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 24
239000003755 preservative agent Substances 0.000 description 24
102000003298 tumor necrosis factor receptor Human genes 0.000 description 24
125000003275 alpha amino acid group Chemical group 0.000 description 23
108060003951 Immunoglobulin Proteins 0.000 description 22
210000004408 hybridoma Anatomy 0.000 description 22
102000018358 immunoglobulin Human genes 0.000 description 22
238000004519 manufacturing process Methods 0.000 description 21
239000002609 medium Substances 0.000 description 21
239000000546 pharmaceutical excipient Substances 0.000 description 21
239000000047 product Substances 0.000 description 21
239000013598 vector Substances 0.000 description 21
241001465754 Metazoa Species 0.000 description 20
238000004458 analytical method Methods 0.000 description 20
230000004927 fusion Effects 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
102000004127 Cytokines Human genes 0.000 description 17
108090000695 Cytokines Proteins 0.000 description 17
150000001875 compounds Chemical class 0.000 description 17
239000013612 plasmid Substances 0.000 description 17
229920001223 polyethylene glycol Polymers 0.000 description 17
230000002335 preservative effect Effects 0.000 description 17
150000003839 salts Chemical class 0.000 description 17
108010047041 Complementarity Determining Regions Proteins 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 16
239000003708 ampul Substances 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
241000283707 Capra Species 0.000 description 15
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 15
239000002299 complementary DNA Substances 0.000 description 15
229960000485 methotrexate Drugs 0.000 description 15
239000002245 particle Substances 0.000 description 15
239000002953 phosphate buffered saline Substances 0.000 description 15
239000003814 drug Substances 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 14
239000002202 Polyethylene glycol Substances 0.000 description 13
239000000443 aerosol Substances 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
150000004665 fatty acids Chemical class 0.000 description 13
238000009396 hybridization Methods 0.000 description 13
230000005847 immunogenicity Effects 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
239000006199 nebulizer Substances 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
239000000654 additive Substances 0.000 description 12
238000013461 design Methods 0.000 description 12
201000010099 disease Diseases 0.000 description 12
239000004094 surface-active agent Substances 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
230000009261 transgenic effect Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 11
229940079593 drug Drugs 0.000 description 11
210000000056 organ Anatomy 0.000 description 11
230000007017 scission Effects 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
150000001720 carbohydrates Chemical class 0.000 description 10
238000010367 cloning Methods 0.000 description 10
230000003053 immunization Effects 0.000 description 10
238000002649 immunization Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
125000005647 linker group Chemical group 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000006228 supernatant Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
241000196324 Embryophyta Species 0.000 description 9
241000282412 Homo Species 0.000 description 9
108010001336 Horseradish Peroxidase Proteins 0.000 description 9
108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
229920001213 Polysorbate 20 Polymers 0.000 description 9
108700019146 Transgenes Proteins 0.000 description 9
230000003321 amplification Effects 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
235000014633 carbohydrates Nutrition 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
230000006870 function Effects 0.000 description 9
210000000265 leukocyte Anatomy 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
210000000822 natural killer cell Anatomy 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
229920000642 polymer Polymers 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
206010052779 Transplant rejections Diseases 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
239000004599 antimicrobial Substances 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
238000002955 isolation Methods 0.000 description 8
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 8
239000003550 marker Substances 0.000 description 8
125000000962 organic group Chemical group 0.000 description 8
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
229920000053 polysorbate 80 Polymers 0.000 description 8
239000000843 powder Substances 0.000 description 8
230000002685 pulmonary effect Effects 0.000 description 8
238000000746 purification Methods 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
239000003053 toxin Substances 0.000 description 8
231100000765 toxin Toxicity 0.000 description 8
108700012359 toxins Proteins 0.000 description 8
241001515965 unidentified phage Species 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 7
241000124008 Mammalia Species 0.000 description 7
210000001744 T-lymphocyte Anatomy 0.000 description 7
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
238000001514 detection method Methods 0.000 description 7
239000012636 effector Substances 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
229920001477 hydrophilic polymer Polymers 0.000 description 7
239000007788 liquid Substances 0.000 description 7
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
238000002156 mixing Methods 0.000 description 7
239000005022 packaging material Substances 0.000 description 7
230000008488 polyadenylation Effects 0.000 description 7
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
239000003380 propellant Substances 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
239000002904 solvent Substances 0.000 description 7
241000894007 species Species 0.000 description 7
239000000758 substrate Substances 0.000 description 7
238000011830 transgenic mouse model Methods 0.000 description 7
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
108010029961 Filgrastim Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 6
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
102000004560 Interleukin-12 Receptors Human genes 0.000 description 6
108010017515 Interleukin-12 Receptors Proteins 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
230000003213 activating effect Effects 0.000 description 6
239000011575 calcium Substances 0.000 description 6
238000010276 construction Methods 0.000 description 6
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 6
108010067396 dornase alfa Proteins 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 6
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
229920001282 polysaccharide Polymers 0.000 description 6
238000010188 recombinant method Methods 0.000 description 6
210000003491 skin Anatomy 0.000 description 6
239000007921 spray Substances 0.000 description 6
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 5
108020004774 Alkaline Phosphatase Proteins 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
208000006673 asthma Diseases 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 5
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
229960000951 mycophenolic acid Drugs 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
230000008569 process Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
108010038379 sargramostim Proteins 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
101150074155 DHFR gene Proteins 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
102000008100 Human Serum Albumin Human genes 0.000 description 4
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
102000057297 Pepsin A Human genes 0.000 description 4
108090000284 Pepsin A Proteins 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
210000000628 antibody-producing cell Anatomy 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 4
229940127219 anticoagulant drug Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
238000002716 delivery method Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
231100000655 enterotoxin Toxicity 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
125000005313 fatty acid group Chemical group 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
102000027596 immune receptors Human genes 0.000 description 4
108091008915 immune receptors Proteins 0.000 description 4
230000028993 immune response Effects 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
238000002513 implantation Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000002502 liposome Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
229940071648 metered dose inhaler Drugs 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229940111202 pepsin Drugs 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
150000004804 polysaccharides Chemical class 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
229960002180 tetracycline Drugs 0.000 description 4
229930101283 tetracycline Natural products 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
229940033663 thimerosal Drugs 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
230000003827 upregulation Effects 0.000 description 4
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
229930182837 (R)-adrenaline Natural products 0.000 description 3
BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 3
ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 3
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 3
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
229930186147 Cephalosporin Natural products 0.000 description 3
241000193403 Clostridium Species 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108010074604 Epoetin Alfa Proteins 0.000 description 3
102000003951 Erythropoietin Human genes 0.000 description 3
108090000394 Erythropoietin Proteins 0.000 description 3
108010008165 Etanercept Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
102000018997 Growth Hormone Human genes 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
244000061176 Nicotiana tabacum Species 0.000 description 3
235000002637 Nicotiana tabacum Nutrition 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241001494479 Pecora Species 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
108010039918 Polylysine Proteins 0.000 description 3
241000288906 Primates Species 0.000 description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
239000004288 Sodium dehydroacetate Substances 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
229940126575 aminoglycoside Drugs 0.000 description 3
239000003263 anabolic agent Substances 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
230000003302 anti-idiotype Effects 0.000 description 3
230000000340 anti-metabolite Effects 0.000 description 3
230000002682 anti-psoriatic effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
239000002111 antiemetic agent Substances 0.000 description 3
229940121375 antifungal agent Drugs 0.000 description 3
239000003429 antifungal agent Substances 0.000 description 3
229940100197 antimetabolite Drugs 0.000 description 3
239000002256 antimetabolite Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
239000003096 antiparasitic agent Substances 0.000 description 3
229940125687 antiparasitic agent Drugs 0.000 description 3
239000003435 antirheumatic agent Substances 0.000 description 3
229940124584 antitussives Drugs 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 3
229960005207 auranofin Drugs 0.000 description 3
229960001799 aurothioglucose Drugs 0.000 description 3
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
229960002170 azathioprine Drugs 0.000 description 3
229960004669 basiliximab Drugs 0.000 description 3
229960000686 benzalkonium chloride Drugs 0.000 description 3
229960001950 benzethonium chloride Drugs 0.000 description 3
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
229940125388 beta agonist Drugs 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
150000007942 carboxylates Chemical class 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229940124587 cephalosporin Drugs 0.000 description 3
150000001780 cephalosporins Chemical class 0.000 description 3
230000008859 change Effects 0.000 description 3
229960002242 chlorocresol Drugs 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960000265 cromoglicic acid Drugs 0.000 description 3
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
229940124570 cycloplegic agent Drugs 0.000 description 3
239000000634 cycloplegic agent Substances 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
239000000430 cytokine receptor antagonist Substances 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
229960002806 daclizumab Drugs 0.000 description 3
108020001096 dihydrofolate reductase Proteins 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229960003530 donepezil Drugs 0.000 description 3
229960000533 dornase alfa Drugs 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
239000000147 enterotoxin Substances 0.000 description 3
229960005139 epinephrine Drugs 0.000 description 3
229960003388 epoetin alfa Drugs 0.000 description 3
229940105423 erythropoietin Drugs 0.000 description 3
239000002834 estrogen receptor modulator Substances 0.000 description 3
229960000403 etanercept Drugs 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
229960004177 filgrastim Drugs 0.000 description 3
229940124307 fluoroquinolone Drugs 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229940015045 gold sodium thiomalate Drugs 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
102000057041 human TNF Human genes 0.000 description 3
229960002927 hydroxychloroquine sulfate Drugs 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
230000008676 import Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000008141 laxative Substances 0.000 description 3
230000002475 laxative effect Effects 0.000 description 3
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
229960000681 leflunomide Drugs 0.000 description 3
239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000003589 local anesthetic agent Substances 0.000 description 3
231100000053 low toxicity Toxicity 0.000 description 3
239000003120 macrolide antibiotic agent Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
239000011707 mineral Substances 0.000 description 3
230000011278 mitosis Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002637 mydriatic agent Substances 0.000 description 3
239000003158 myorelaxant agent Substances 0.000 description 3
229940029345 neupogen Drugs 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000008177 pharmaceutical agent Substances 0.000 description 3
238000001050 pharmacotherapy Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
229920000656 polylysine Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
229920001451 polypropylene glycol Polymers 0.000 description 3
229940068977 polysorbate 20 Drugs 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229940107568 pulmozyme Drugs 0.000 description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
229960002530 sargramostim Drugs 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
230000011664 signaling Effects 0.000 description 3
229940079839 sodium dehydroacetate Drugs 0.000 description 3
235000019259 sodium dehydroacetate Nutrition 0.000 description 3
DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 3
AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
150000005846 sugar alcohols Chemical class 0.000 description 3
229940124530 sulfonamide Drugs 0.000 description 3
150000003456 sulfonamides Chemical class 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
229960001685 tacrine Drugs 0.000 description 3
YLJREFDVOIBQDA-UHFFFAOYSA-O tacrine(1+) Chemical compound C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-O 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
230000005030 transcription termination Effects 0.000 description 3
230000037317 transdermal delivery Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
108020005065 3' Flanking Region Proteins 0.000 description 2
102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
101150078577 Adora2b gene Proteins 0.000 description 2
241000607534 Aeromonas Species 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
208000012657 Atopic disease Diseases 0.000 description 2
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical class O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010060880 Monoclonal gammopathy Diseases 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
208000002774 Paraproteinemias Diseases 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
206010036105 Polyneuropathy Diseases 0.000 description 2
208000012654 Primary biliary cholangitis Diseases 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
230000006819 RNA synthesis Effects 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
206010039085 Rhinitis allergic Diseases 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
241000607768 Shigella Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
229910052770 Uranium Inorganic materials 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
241000607598 Vibrio Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
201000010105 allergic rhinitis Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
239000002269 analeptic agent Substances 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
208000003455 anaphylaxis Diseases 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000009830 antibody antigen interaction Effects 0.000 description 2
239000000228 antimanic agent Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000000164 antipsychotic agent Substances 0.000 description 2
239000003434 antitussive agent Substances 0.000 description 2
239000003699 antiulcer agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Chemical class 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
150000001991 dicarboxylic acids Chemical class 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
DGXRZJSPDXZJFG-UHFFFAOYSA-N docosanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCCCCCC(O)=O DGXRZJSPDXZJFG-UHFFFAOYSA-N 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000005684 electric field Effects 0.000 description 2
208000030172 endocrine system disease Diseases 0.000 description 2
230000000688 enterotoxigenic effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000009585 enzyme analysis Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
239000003326 hypnotic agent Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
230000001861 immunosuppressant effect Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
229940087875 leukine Drugs 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000845 maltitol Substances 0.000 description 2
235000010449 maltitol Nutrition 0.000 description 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
229940035436 maltitol Drugs 0.000 description 2
229940127554 medical product Drugs 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
230000003533 narcotic effect Effects 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
239000000842 neuromuscular blocking agent Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
NOUWNNABOUGTDQ-UHFFFAOYSA-N octane Chemical compound CCCCCCC[CH2+] NOUWNNABOUGTDQ-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
230000007824 polyneuropathy Effects 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000002702 ribosome display Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
239000013595 supernatant sample Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940127230 sympathomimetic drug Drugs 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000011975 tartaric acid Chemical class 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 2
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000005026 transcription initiation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical class [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
241000607516 Aeromonas caviae Species 0.000 description 1
241000607528 Aeromonas hydrophila Species 0.000 description 1
241000607522 Aeromonas sobria Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108020005035 Algal DNA Proteins 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
108020004998 Chloroplast DNA Proteins 0.000 description 1
108020005133 Chloroplast RNA Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
241000193155 Clostridium botulinum Species 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
241001269524 Dura Species 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010058872 Fungal sepsis Diseases 0.000 description 1
101710085030 Gene 32 protein Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000989913 Gunnera petaloidea Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019315 Heart transplant rejection Diseases 0.000 description 1
101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
101000958041 Homo sapiens Musculin Proteins 0.000 description 1
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010022491 Insulin resistant diabetes Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010023439 Kidney transplant rejection Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
206010024715 Liver transplant rejection Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000035809 Lymphohistiocytosis Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
206010058858 Meningococcal bacteraemia Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241001045988 Neogene Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
206010053869 POEMS syndrome Diseases 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000606999 Plesiomonas shigelloides Species 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920001273 Polyhydroxy acid Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010039094 Rhinitis perennial Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010062164 Seronegative arthritis Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000607766 Shigella boydii Species 0.000 description 1
241000607764 Shigella dysenteriae Species 0.000 description 1
241000607762 Shigella flexneri Species 0.000 description 1
241000607760 Shigella sonnei Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
208000004732 Systemic Vasculitis Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
241000188156 Tamu Species 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102000018594 Tumour necrosis factor Human genes 0.000 description 1
108050007852 Tumour necrosis factor Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010048709 Urosepsis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047400 Vibrio infections Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
101150063325 ab gene Proteins 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
231100000230 acceptable toxicity Toxicity 0.000 description 1
YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003561 anti-manic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229940114078 arachidonate Drugs 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
229940127225 asthma medication Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229940116224 behenate Drugs 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
101150034785 gamma gene Proteins 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
108060003196 globin Proteins 0.000 description 1
239000000174 gluconic acid Chemical class 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
102000005396 glutamine synthetase Human genes 0.000 description 1
108020002326 glutamine synthetase Proteins 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
101150106093 gpt gene Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
229920000591 gum Polymers 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
150000004687 hexahydrates Chemical class 0.000 description 1
102000046949 human MSC Human genes 0.000 description 1
102000054751 human RUNX1T1 Human genes 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
238000012332 laboratory investigation Methods 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
230000014725 late viral mRNA transcription Effects 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229960002337 magnesium chloride Drugs 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
208000022089 meningococcemia Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
108091064355 mitochondrial RNA Proteins 0.000 description 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
150000002763 monocarboxylic acids Chemical class 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000003232 mucoadhesive effect Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
150000002790 naphthalenes Chemical class 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
SPIFDSWFDKNERT-UHFFFAOYSA-N nickel;hydrate Chemical compound O.[Ni] SPIFDSWFDKNERT-UHFFFAOYSA-N 0.000 description 1
ZLGLJDGHKLKKIV-UHFFFAOYSA-M nitrosooxy(phenyl)mercury Chemical compound [O-]N=O.[Hg+]C1=CC=CC=C1 ZLGLJDGHKLKKIV-UHFFFAOYSA-M 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000010422 painting Methods 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229960001476 pentoxifylline Drugs 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000008180 pharmaceutical surfactant Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
125000002743 phosphorus functional group Chemical group 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
238000005222 photoaffinity labeling Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229940116406 poloxamer 184 Drugs 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
150000007519 polyprotic acids Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
108010066381 preproinsulin Proteins 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
206010040400 serum sickness Diseases 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229940007046 shigella dysenteriae Drugs 0.000 description 1
229940115939 shigella sonnei Drugs 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
229960003676 tenidap Drugs 0.000 description 1
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
CWXZMNMLGZGDSW-UHFFFAOYSA-N tetracontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O CWXZMNMLGZGDSW-UHFFFAOYSA-N 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
229940073585 tromethamine hydrochloride Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
208000009852 uremia Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000007879 vasectomy Methods 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)

NO20030614A 2000-08-07 2003-02-07 Nukleinsyrer, anti-IL-12-antistoff, sammensetning inneholdende denne samt vertscelle. NO330903B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US22335800P	2000-08-07	2000-08-07
US23682700P	2000-09-29	2000-09-29
US09/920,262 US6902734B2 (en)	2000-08-07	2001-08-01	Anti-IL-12 antibodies and compositions thereof
PCT/US2001/024720 WO2002012500A2 (en)	2000-08-07	2001-08-07	Anti-il-12 antibodies, compositions, methods and uses

Publications (3)

Publication Number	Publication Date
NO20030614D0 NO20030614D0 (no)	2003-02-07
NO20030614L NO20030614L (no)	2003-04-02
NO330903B1 true NO330903B1 (no)	2011-08-15

Family

ID=27397221

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20030614A NO330903B1 (no)	2000-08-07	2003-02-07	Nukleinsyrer, anti-IL-12-antistoff, sammensetning inneholdende denne samt vertscelle.
NO2011023C NO2011023I1 (no)	2000-08-07	2011-10-04	Stelara- Ustekinumab. Ustekinimab er et humant IgG1k monoklonalt antistoff som bindes til p40 proteinsubenheten til human cytokinene IL-12 og IL 23, produsert i en murin myelomcelle ved hjelp av rekombinant DNA teknologi
NO2020005C NO2020005I1 (no)	2000-08-07	2020-03-11	ustekinumab. Forlenget SPC

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2011023C NO2011023I1 (no)	2000-08-07	2011-10-04	Stelara- Ustekinumab. Ustekinimab er et humant IgG1k monoklonalt antistoff som bindes til p40 proteinsubenheten til human cytokinene IL-12 og IL 23, produsert i en murin myelomcelle ved hjelp av rekombinant DNA teknologi
NO2020005C NO2020005I1 (no)	2000-08-07	2020-03-11	ustekinumab. Forlenget SPC

Country Status (33)

Country	Link
US (15)	US6902734B2 (el)
EP (5)	EP2305817B1 (el)
JP (4)	JP4731094B2 (el)
KR (1)	KR100823576B1 (el)
CN (2)	CN1468309A (el)
AR (1)	AR030134A1 (el)
AT (1)	ATE431412T1 (el)
AU (2)	AU2001281137B2 (el)
BR (1)	BRPI0113109B8 (el)
CA (1)	CA2418961C (el)
CL (1)	CL2009000575A1 (el)
CY (7)	CY1109149T1 (el)
DE (2)	DE60138711D1 (el)
DK (4)	DK3178934T3 (el)
EA (1)	EA006673B1 (el)
ES (4)	ES2747573T3 (el)
FR (1)	FR09C0021I2 (el)
HK (1)	HK1135991A1 (el)
HR (1)	HRP20030087B1 (el)
HU (1)	HU228009B1 (el)
IL (1)	IL154325A (el)
LT (6)	LT2305817T (el)
LU (3)	LU91584I2 (el)
ME (1)	ME00326B (el)
MX (1)	MXPA03001229A (el)
MY (1)	MY133377A (el)
NL (1)	NL300390I2 (el)
NO (3)	NO330903B1 (el)
NZ (2)	NZ524145A (el)
PT (4)	PT1309692E (el)
RS (1)	RS50477B (el)
SI (4)	SI2305817T1 (el)
WO (1)	WO2002012500A2 (el)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277969B1 (en) *	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US6830751B1 (en)	1994-03-14	2004-12-14	Genetics Institute, Llc	Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7883704B2 (en) *	1999-03-25	2011-02-08	Abbott Gmbh & Co. Kg	Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
US20050249735A1 (en) *	2000-08-07	2005-11-10	Centocor, Inc.	Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6902734B2 (en) *	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
WO2003083071A2 (en) *	2002-03-26	2003-10-09	Centocor, Inc.	Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
AU2003220557A1 (en) *	2002-03-26	2003-10-13	Centocor, Inc.	Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
US7273889B2 (en) *	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
ATE439166T1 (de) *	2002-10-30	2009-08-15	Genentech Inc	Hemmung von il-17 produktion
US20060034845A1 (en) *	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CN102584997A (zh) *	2002-11-08	2012-07-18	埃博灵克斯股份有限公司	针对肿瘤坏死因子-α的单结构域抗体及其用途
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (en) *	2002-11-08	2004-05-21	Ablynx N.V.	Stabilized single domain antibodies
US20100003253A1 (en) *	2002-11-08	2010-01-07	Ablynx N.V.	Single domain antibodies directed against epidermal growth factor receptor and uses therefor
EP1648998B1 (en) *	2003-07-18	2014-10-01	Amgen Inc.	Specific binding agents to hepatocyte growth factor
GB0329146D0 (en) *	2003-12-16	2004-01-21	Glaxosmithkline Biolog Sa	Vaccine
CN1942201B (zh) *	2004-02-17	2012-06-20	先灵公司	调节il-23活性的方法；相关试剂
ES2440777T3 (es) *	2004-12-21	2014-01-30	Janssen Biotech, Inc.	Vectores basados en anticuerpo anti-il-12, células huéspedes y métodos de producción y usos
CA2591813A1 (en) *	2004-12-21	2006-06-29	Centocor, Inc.	Anti-il-12 antibodies, epitopes, compositions, methods and uses
WO2006112838A1 (en) *	2005-04-18	2006-10-26	Xtl Biopharmaceuticals Ltd.	Stabilized anti-hepatitis b (hbv) antibody formulations
CN103145840A (zh) *	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
JP2007172129A (ja) *	2005-12-20	2007-07-05	Sony Corp	不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
WO2007137328A1 (en) *	2006-05-26	2007-12-06	Apollo Life Sciences Limited	An isolated il-12 molecule or chimeric molecules thereof
WO2008070647A1 (en) *	2006-12-07	2008-06-12	Wyeth	Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
KR20150038227A (ko)	2007-01-16	2015-04-08	애브비 인코포레이티드	건선의 치료방법
EP2142565A4 (en)	2007-03-29	2010-03-31	Abbott Lab	CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
WO2009114040A2 (en) *	2007-09-28	2009-09-17	Centocor Ortho Biotech Inc.	Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
JP2011504740A (ja)	2007-11-27	2011-02-17	アブリンクスエン．ヴェー．	ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
EP2274333A4 (en)	2008-03-18	2011-06-15	Abbott Lab	PROCESS FOR TREATING PSORIASIS
WO2009136286A2 (en)	2008-05-05	2009-11-12	Novimmune Sa	Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
CA2739455A1 (en) *	2008-10-20	2010-04-29	Abbott Laboratories	Antibodies that bind to il-12 and methods of purifying the same
EP2346897A2 (en)	2008-10-20	2011-07-27	Abbott Laboratories	Viral inactivation during purification of antibodies
NZ606283A (en) *	2008-11-28	2014-08-29	Abbvie Inc	Stable antibody compositions and methods for stabilizing same
KR101811886B1 (ko)	2009-05-05	2017-12-22	노비뮨 에스 에이	항―ｉｌ―17ｆ 항체 및 이의 사용 방법
KR20120112384A (ko) *	2009-09-14	2012-10-11	애보트 게엠베하 운트 콤파니 카게	건선을 치료하는 방법
EP3372617B1 (en)	2010-04-02	2024-07-24	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CA2821992A1 (en)	2010-10-01	2012-04-05	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
TW201309330A (zh) *	2011-01-28	2013-03-01	Abbott Lab	包含糖基化抗體之組合物及其用途
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
SG11201401196WA (en)	2011-10-03	2014-05-29	Moderna Therapeutics Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SG10201604896TA (en)	2011-12-16	2016-08-30	Moderna Therapeutics Inc	Modified nucleoside, nucleotide, and nucleic acid compositions
US20150010544A1 (en)	2011-12-16	2015-01-08	Synthon Biopharmaceuticals B.V.	Compounds and methods for treating inflammatory diseases
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151670A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of nuclear proteins
JP6267689B2 (ja) *	2012-05-10	2018-01-24	バイオアトラ、エルエルシー	多重特異性モノクローナル抗体
US9803010B2 (en)	2012-06-27	2017-10-31	Merck Sharp & Dohme Corp.	Crystalline anti-human IL-23p19 antibodies
EP4074834A1 (en)	2012-11-26	2022-10-19	ModernaTX, Inc.	Terminally modified rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9603775B2 (en)	2013-04-24	2017-03-28	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
ES2887549T3 (es)	2014-09-03	2021-12-23	Boehringer Ingelheim Int	Compuesto dirigido a IL-23A y TNF-alfa y usos del mismo
US20180298340A1 (en) *	2015-04-24	2018-10-18	The Regents Of The University Of California	Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
WO2017070561A1 (en) *	2015-10-23	2017-04-27	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
EP3436477A2 (en) *	2016-03-29	2019-02-06	Janssen Biotech, Inc.	Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
US20200347126A1 (en)	2016-08-03	2020-11-05	Fyb 202 Project Gmbh	Production of Biosimilar Ustekinumab In CHO Cells
JP2020502261A (ja)	2016-11-16	2020-01-23	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で乾癬を治療する方法
US20180193003A1 (en)	2016-12-07	2018-07-12	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
EP3554540B1 (en)	2016-12-14	2023-08-02	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3573658A4 (en)	2017-01-30	2021-07-21	Janssen Biotech, Inc.	ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
KR20240038148A (ko)	2017-02-07	2024-03-22	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US12043845B2 (en)	2017-06-08	2024-07-23	Polpharma Biologics S.A.	Methods of cell culture
TW201922780A (zh) *	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en)	2017-12-01	2019-06-06	Fyb 202 Project Gmbh	Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
JP7421500B2 (ja)	2018-05-18	2024-01-24	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
TR201808283A2 (tr) *	2018-06-11	2018-07-23	Centurion Ilac San Ve Tic A S	Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
US20230009902A1 (en)	2018-06-20	2023-01-12	Progenity, Inc.	Treatment of a disease or condition in a tissue orginating from the endoderm
EP3810268A1 (en)	2018-06-20	2021-04-28	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20200061015A1 (en)	2018-08-23	2020-02-27	Janssen Biotech, Inc.	Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
WO2020065532A1 (en)	2018-09-24	2020-04-02	Janssen Biotech, Inc.	Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
WO2020106757A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3883607A4 (en)	2018-11-20	2022-08-17	Janssen Biotech, Inc.	SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
JP2022518208A (ja)	2019-01-15	2022-03-14	ヤンセンバイオテツク，インコーポレーテツド	若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
KR20210118878A (ko)	2019-01-23	2021-10-01	얀센 바이오테크 인코포레이티드	건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
KR20210142002A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물을 생성하기 위한 제조 방법
EA202192508A1 (ru)	2019-03-14	2022-03-29	Янссен Байотек, Инк.	Способы получения композиций антитела к фно
JP2022526881A (ja)	2019-03-14	2022-05-27	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
WO2020188466A1 (en) *	2019-03-18	2020-09-24	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CA3138241A1 (en)	2019-05-23	2020-11-26	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
BR112021024401A2 (pt)	2019-06-03	2022-04-19	Janssen Biotech Inc	Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
JP2022536279A (ja)	2019-06-03	2022-08-15	ヤンセンバイオテツク，インコーポレーテツド	乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
EP4008727A4 (en) *	2019-07-30	2024-01-17	Akeso Biopharma, Inc.	HUMANIZED ANTIBODY DIRECTED AGAINST THE P40 PROTEIN DOMAIN AND ITS USE
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
EP4309722A3 (en)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2020409124A1 (en)	2019-12-20	2022-06-30	Novarock Biotherapeutics, Ltd.	Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2022024065A1 (en) *	2020-07-30	2022-02-03	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CN118139883A (zh)	2021-07-09	2024-06-04	詹森生物科技公司	用于生产抗tnf抗体组合物的制造方法
WO2023281463A1 (en)	2021-07-09	2023-01-12	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
MX2024010773A (es)	2022-03-03	2024-09-10	Pfizer Inc	Anticuerpos multiespecificos y usos de estos.
US20240059799A1 (en)	2022-05-11	2024-02-22	Pfizer Inc.	Anti-tl1a antibodies and methods of use thereof

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US122464A (en)		1872-01-02		Improvement in cheese-hoops
US941234A (en)	1909-02-25	1909-11-23	Frank De Clercq	Syrup-percolator.
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4309989A (en)	1976-02-09	1982-01-12	The Curators Of The University Of Missouri	Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr)	1976-10-23	1978-07-21	Choay Sa	Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US5149636A (en)	1982-03-15	1992-09-22	Trustees Of Columbia University In The City Of New York	Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
DE3590766T (el)	1985-03-30	1987-04-23
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
SE448277B (sv)	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en)	1985-05-31	1988-08-23	President And Fellows Of Harvard College	Gene amplification
GB8517895D0 (en)	1985-07-16	1985-08-21	Technology Licence Co Ltd	Monoclonal antibodies
US4870163A (en)	1985-08-29	1989-09-26	New York Blood Center, Inc.	Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
DE3600905A1 (de)	1986-01-15	1987-07-16	Ant Nachrichtentech	Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv)	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en)	1986-07-08	1988-08-30	Massachusetts Institute Of Technology	Ultrasound enhancement of transdermal drug delivery
WO1988001213A1 (en)	1986-08-18	1988-02-25	Clinical Technologies Associates, Inc.	Delivery systems for pharmacological agents
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3631229A1 (de)	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4795699A (en)	1987-01-14	1989-01-03	President And Fellows Of Harvard College	T7 DNA polymerase
US4921794A (en)	1987-01-14	1990-05-01	President And Fellows Of Harvard College	T7 DNA polymerase
EP0279582A3 (en)	1987-02-17	1989-10-18	Pharming B.V.	Dna sequences to target proteins to the mammary gland for efficient secretion
ATE114723T1 (de)	1987-03-02	1994-12-15	Enzon Lab Inc	Organismus als träger für ''single chain antibody domain (scad)''.
EP0288088B1 (en)	1987-04-24	1994-03-09	Teijin Limited	Detection of tumor necrosis factor; monoclonal antibody and kit
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en)	1987-07-24	2001-05-22	Randy R. Robinson	Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en)	1987-09-02	1990-07-03	Genex Corporation	Incremental macromolecule construction methods
EP0308936B1 (en)	1987-09-23	1994-07-06	Bristol-Myers Squibb Company	Antibody heteroconjugates for the killing of HIV-infected cells
DE68926882T2 (de)	1988-01-11	1997-02-13	Xoma Corp	Plasmidvektor mit pectatlyase-signalsequenz
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5142033A (en)	1988-09-23	1992-08-25	Hoffmann-La Roche Inc.	Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en)	1988-09-23	1991-11-19	Cetus Corporation	Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en)	1988-09-23	1992-02-25	Cetus Corporation	Structure-independent dna amplification by the polymerase chain reaction
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US4987893A (en)	1988-10-12	1991-01-29	Rochal Industries, Inc.	Conformable bandage and coating material
US5750373A (en)	1990-12-03	1998-05-12	Genentech, Inc.	Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5811523A (en)	1988-11-10	1998-09-22	Trinchieri; Giorgio	Antibodies to natural killer stimulatory factor
ATE140483T1 (de)	1988-11-10	1996-08-15	Genetics Inst	Natürlicher killerzellen-stimulationsfaktor
US5457038A (en)	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
KR0184860B1 (ko)	1988-11-11	1999-04-01	메디칼 리써어치 카운실	단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US4994370A (en)	1989-01-03	1991-02-19	The United States Of America As Represented By The Department Of Health And Human Services	DNA amplification technique
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en)	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de)	1989-03-23	1990-09-27	Boehringer Mannheim Gmbh	Verfahren zur herstellung bispezifischer antikoerper
CA2057923A1 (en)	1989-05-16	1990-11-17	William D. Huse	Co-expression of heteromeric receptors
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
CA2016841C (en)	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
ATE144793T1 (de)	1989-06-29	1996-11-15	Medarex Inc	Bispezifische reagenzien für die aids-therapie
DE10399036I1 (de)	1989-08-07	2004-04-01	Peptide Technology Ltd	Bindeligande für Tumornekrosisfaktor.
AU638762B2 (en)	1989-10-05	1993-07-08	Optein Inc	Cell-free synthesis and isolation of novel genes and polypeptides
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5780597A (en) *	1989-12-22	1998-07-14	Hoffmann-La Roche Inc.	Monoclonal antibodies to cytotoxic lymphocyte maturation factor
EP0433827B1 (en)	1989-12-22	1998-03-04	F. Hoffmann-La Roche Ag	Cytotoxic lymphocyte maturation factor
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
TW212184B (el)	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
CA2084307A1 (en)	1990-06-01	1991-12-02	Cetus Oncology Corporation	Compositions and methods for identifying biologically active molecules
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
EP0547065B1 (en)	1990-06-29	2001-08-29	Large Scale Biology Corporation	Melanin production by transformed microorganisms
US5580734A (en)	1990-07-13	1996-12-03	Transkaryotic Therapies, Inc.	Method of producing a physical map contigous DNA sequences
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da)	1990-08-29	2005-10-24	Genpharm Int	Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
WO1992005258A1 (en)	1990-09-20	1992-04-02	La Trobe University	Gene encoding barley enzyme
GB9022648D0 (en)	1990-10-18	1990-11-28	Charing Cross Sunley Research	Polypeptide and its use
DE69128253T2 (de)	1990-10-29	1998-06-18	Chiron Corp	Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
AU1435492A (en)	1991-02-21	1992-09-15	Gilead Sciences, Inc.	Aptamer specific for biomolecules and method of making
US5404871A (en)	1991-03-05	1995-04-11	Aradigm	Delivery of aerosol medications for inspiration
WO1992016221A1 (en)	1991-03-15	1992-10-01	Synergen, Inc.	Pegylation of polypeptides
WO1992018619A1 (en)	1991-04-10	1992-10-29	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
EP0586505A1 (en)	1991-05-14	1994-03-16	Repligen Corporation	Heteroconjugate antibodies for treatment of hiv infection
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP1693080A3 (en)	1991-07-02	2007-07-25	Nektar Therapeutics	Method and device for delivering aeroslized medicaments
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
CA2103887C (en)	1991-12-13	2005-08-30	Gary M. Studnicka	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5667988A (en)	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de)	1992-03-10	1993-09-16	Goldwell Ag	Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994006498A1 (en)	1992-09-23	1994-03-31	Fisons Plc	Inhalation device
WO1994008038A1 (en)	1992-10-02	1994-04-14	Trustees Of Dartmouth College	Bispecific reagents for redirected targeting of low density lipoprotein
SK51695A3 (en)	1992-10-19	1995-11-08	Dura Pharma Inc	Dry powder medicament inhaler
US5643252A (en)	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
WO1994012520A1 (en)	1992-11-20	1994-06-09	Enzon, Inc.	Linker for linked fusion polypeptides
US5849695A (en)	1993-01-13	1998-12-15	The Regents Of The University Of California	Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
WO1994016970A1 (en)	1993-01-19	1994-08-04	Glaxo Group Limited	Device
US5300478A (en) *	1993-01-28	1994-04-05	Zeneca Limited	Substituted fused pyrazolo compounds
CZ206195A3 (en)	1993-02-12	1996-04-17	Univ Leland Stanford Junior	Controlled transcription of target genes and other biological materials
EP0614989A1 (en)	1993-02-17	1994-09-14	MorphoSys AG	A method for in vivo selection of ligand-binding proteins
US5770428A (en)	1993-02-17	1998-06-23	Wisconsin Alumni Research Foundation	Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
AU6819494A (en)	1993-04-26	1994-11-21	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
AU667438B2 (en) *	1993-04-30	1996-03-21	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Method of purifying hydrophobic polypeptide
DE4315127A1 (de) *	1993-05-07	1994-11-10	Behringwerke Ag	Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) *	1993-07-02	2007-08-28	Maurice Kent Gately	P40 homodimer of interleukin-12
US5514670A (en)	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de)	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en)	1995-08-04	1998-09-29	Massachusetts Insitiute Of Technology	Transdermal delivery of encapsulated drugs
SE9304060D0 (sv)	1993-12-06	1993-12-06	Bioinvent Int Ab	Sätt att selektera specifika bakteriofager
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
WO1995024220A1 (en)	1994-03-07	1995-09-14	Medarex, Inc.	Bispecific molecules having clinical utilities
ZA95960B (en) *	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
WO1995029239A2 (en)	1994-04-22	1995-11-02	Corixa Corporation	Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
US5763733A (en)	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US5549551A (en)	1994-12-22	1996-08-27	Advanced Cardiovascular Systems, Inc.	Adjustable length balloon catheter
US6086875A (en) *	1995-01-17	2000-07-11	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of immunogens
US5891680A (en) *	1995-02-08	1999-04-06	Whitehead Institute For Biomedical Research	Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6037453A (en)	1995-03-15	2000-03-14	Genentech, Inc.	Immunoglobulin variants
US5656730A (en)	1995-04-07	1997-08-12	Enzon, Inc.	Stabilized monomeric protein compositions
CA2761116A1 (en) *	1995-04-27	1996-10-31	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US5853697A (en)	1995-10-25	1998-12-29	The United States Of America, As Represented By The Department Of Health & Human Services	Methods of treating established colitis using antibodies against IL-12
GB9526100D0 (en)	1995-12-20	1996-02-21	Intersurgical Ltd	Nebulizer
CA2241880A1 (en)	1996-01-03	1997-07-17	Glaxo Group Limited	Inhalation device
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
DE19624387C2 (de)	1996-06-19	1999-08-19	Hatz Motoren	Kaltstartvorrichtung
EP0826695B1 (de)	1996-09-03	2001-12-12	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern
DK0942968T3 (da)	1996-12-03	2008-06-23	Amgen Fremont Inc	Fuldt humane antistoffer, der binder EGFR
US5879681A (en)	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US6086876A (en)	1997-02-07	2000-07-11	The Wistar Insitute	Methods and compositions for the inhibition of interleukin-12 production
US5921447A (en)	1997-02-13	1999-07-13	Glaxo Wellcome Inc.	Flow-through metered aerosol dispensing apparatus and method of use thereof
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en)	1997-05-29	2004-03-28	Univ Ben Gurion	A system for administering drugs through the skin
US6060284A (en) *	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
EP1049717B1 (en) *	1998-01-23	2007-03-21	F. Hoffmann-La Roche Ag	Antibodies against human il-12
DE69927520T2 (de)	1998-12-09	2006-06-22	Protein Design Labs, Inc., Fremont	Verwendung von il-12 antikörpern zur behandlung von psoriasis
PL409839A1 (pl)	1999-03-25	2015-03-30	Abbott Gmbh & Co.Kg	Ludzkie przeciwciała, które wiążą ludzką IL-12 i sposoby ich wytwarzania
US6914128B1 (en) *	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
AU7127600A (en)	1999-09-17	2001-04-17	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) *	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
AU2003247411A1 (en)	2002-05-23	2003-12-12	Cognis Corporation	NON-REVERTIBLE Beta-OXIDATION BLOCKED CANDIDA TROPICALIS
DE102007030072A1 (de)	2007-06-29	2009-01-02	BSH Bosch und Siemens Hausgeräte GmbH	Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät
JP5470817B2 (ja)	2008-03-10	2014-04-16	日産自動車株式会社	電池用電極およびこれを用いた電池、並びにその製造方法
JP5155355B2 (ja)	2010-04-07	2013-03-06	レノボ・シンガポール・プライベート・リミテッド	無線基地局の自律的な負荷調整が可能な無線端末装置
US9619256B1 (en)	2012-06-27	2017-04-11	EMC IP Holding Company LLC	Multi site and multi tenancy
JP6136279B2 (ja)	2013-01-15	2017-05-31	株式会社ジェイテクト	転がり軸受装置
TWI503850B (zh)	2013-03-22	2015-10-11	Polytronics Technology Corp	過電流保護元件
TWI510996B (zh)	2013-10-03	2015-12-01	Acer Inc	控制觸控面板的方法以及使用該方法的可攜式電腦
US9205258B2 (en)	2013-11-04	2015-12-08	ElectroCore, LLC	Nerve stimulator system
US9816280B1 (en)	2016-11-02	2017-11-14	Matthew Reitnauer	Portable floor

2001
- 2001-08-01 US US09/920,262 patent/US6902734B2/en not_active Expired - Lifetime
- 2001-08-07 DK DK17153336.7T patent/DK3178934T3/da active
- 2001-08-07 RS YUP-93/03A patent/RS50477B/sr unknown
- 2001-08-07 KR KR1020037001843A patent/KR100823576B1/ko active Protection Beyond IP Right Term
- 2001-08-07 ES ES17153336T patent/ES2747573T3/es not_active Expired - Lifetime
- 2001-08-07 EP EP10184116.1A patent/EP2305817B1/en not_active Expired - Lifetime
- 2001-08-07 SI SI200131066T patent/SI2305817T1/en unknown
- 2001-08-07 ES ES09006396.7T patent/ES2624502T3/es not_active Expired - Lifetime
- 2001-08-07 AR ARP010103780A patent/AR030134A1/es active IP Right Grant
- 2001-08-07 WO PCT/US2001/024720 patent/WO2002012500A2/en active IP Right Grant
- 2001-08-07 JP JP2002517788A patent/JP4731094B2/ja not_active Expired - Lifetime
- 2001-08-07 EA EA200300137A patent/EA006673B1/ru not_active IP Right Cessation
- 2001-08-07 EP EP17153336.7A patent/EP3178934B1/en not_active Expired - Lifetime
- 2001-08-07 DK DK01959598T patent/DK1309692T3/da active
- 2001-08-07 DK DK10184116.1T patent/DK2305817T3/en active
- 2001-08-07 NZ NZ524145A patent/NZ524145A/en not_active IP Right Cessation
- 2001-08-07 DE DE60138711T patent/DE60138711D1/de not_active Expired - Lifetime
- 2001-08-07 MY MYPI20013706 patent/MY133377A/en unknown
- 2001-08-07 PT PT01959598T patent/PT1309692E/pt unknown
- 2001-08-07 BR BRPI0113109A patent/BRPI0113109B8/pt active IP Right Grant
- 2001-08-07 SI SI200130913T patent/SI1309692T1/sl unknown
- 2001-08-07 SI SI200131070T patent/SI3178934T1/sl unknown
- 2001-08-07 NZ NZ535865A patent/NZ535865A/en not_active IP Right Cessation
- 2001-08-07 CA CA002418961A patent/CA2418961C/en not_active Expired - Lifetime
- 2001-08-07 ME MEP-2008-444A patent/ME00326B/me unknown
- 2001-08-07 EP EP09006396.7A patent/EP2090657B1/en not_active Expired - Lifetime
- 2001-08-07 PT PT101841161T patent/PT2305817T/pt unknown
- 2001-08-07 HU HU0302378A patent/HU228009B1/hu active Protection Beyond IP Right Term
- 2001-08-07 IL IL154325A patent/IL154325A/en active Protection Beyond IP Right Term
- 2001-08-07 MX MXPA03001229A patent/MXPA03001229A/es active IP Right Grant
- 2001-08-07 LT LTEP10184116.1T patent/LT2305817T/lt unknown
- 2001-08-07 LT LTEP09006396.7T patent/LT2090657T/lt unknown
- 2001-08-07 DE DE122009000025C patent/DE122009000025I1/de active Pending
- 2001-08-07 AT AT01959598T patent/ATE431412T1/de active
- 2001-08-07 DK DK09006396.7T patent/DK2090657T3/en active
- 2001-08-07 PT PT90063967T patent/PT2090657T/pt unknown
- 2001-08-07 CN CNA018169619A patent/CN1468309A/zh active Pending
- 2001-08-07 SI SI200131060A patent/SI2090657T1/sl unknown
- 2001-08-07 LT LTEP17153336.7T patent/LT3178934T/lt unknown
- 2001-08-07 ES ES01959598T patent/ES2323760T3/es not_active Expired - Lifetime
- 2001-08-07 EP EP19179253.0A patent/EP3597752A1/en not_active Withdrawn
- 2001-08-07 AU AU2001281137A patent/AU2001281137B2/en not_active Expired
- 2001-08-07 AU AU8113701A patent/AU8113701A/xx active Pending
- 2001-08-07 PT PT171533367T patent/PT3178934T/pt unknown
- 2001-08-07 ES ES10184116.1T patent/ES2647220T3/es not_active Expired - Lifetime
- 2001-08-07 CN CN200810100025.3A patent/CN101550190B/zh not_active Expired - Lifetime
- 2001-08-07 EP EP01959598A patent/EP1309692B1/en not_active Expired - Lifetime
2003
- 2003-02-07 HR HRP20030087AA patent/HRP20030087B1/xx not_active IP Right Cessation
- 2003-02-07 NO NO20030614A patent/NO330903B1/no not_active IP Right Cessation
2004
- 2004-08-06 US US10/912,994 patent/US20050002937A1/en not_active Abandoned
- 2004-10-28 US US10/975,708 patent/US7166285B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,883 patent/US7279157B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,740 patent/US7063964B2/en not_active Expired - Lifetime
2007
- 2007-01-29 US US11/668,256 patent/US7560247B2/en not_active Expired - Lifetime
2009
- 2009-03-11 CL CL2009000575A patent/CL2009000575A1/es unknown
- 2009-05-13 NL NL300390C patent/NL300390I2/nl unknown
- 2009-05-13 FR FR09C0021C patent/FR09C0021I2/fr active Active
- 2009-05-15 LT LTPA2009002C patent/LTC1309692I2/lt unknown
- 2009-06-09 CY CY20091100601T patent/CY1109149T1/el unknown
- 2009-06-12 CY CY2009007C patent/CY2009007I2/el unknown
- 2009-07-09 US US12/500,120 patent/US7887807B2/en not_active Expired - Fee Related
- 2009-07-10 LU LU91584C patent/LU91584I2/fr unknown
2010
- 2010-01-05 HK HK10100042.6A patent/HK1135991A1/zh not_active IP Right Cessation
- 2010-12-17 US US12/971,626 patent/US8084233B2/en not_active Expired - Fee Related
2011
- 2011-03-10 JP JP2011052971A patent/JP2011173884A/ja not_active Withdrawn
- 2011-10-04 NO NO2011023C patent/NO2011023I1/no not_active IP Right Cessation
- 2011-10-26 JP JP2011235204A patent/JP2012025779A/ja active Pending
- 2011-11-18 US US13/299,874 patent/US8329171B2/en not_active Expired - Lifetime
2012
- 2012-11-07 US US13/670,918 patent/US8703141B2/en not_active Expired - Fee Related
2014
- 2014-02-26 US US14/190,893 patent/US9409984B2/en not_active Expired - Fee Related
- 2014-09-22 JP JP2014192690A patent/JP6076303B2/ja not_active Expired - Lifetime
2016
- 2016-06-30 US US15/198,678 patent/US9676848B2/en not_active Expired - Lifetime
2017
- 2017-05-01 US US15/583,487 patent/US10259867B2/en not_active Expired - Fee Related
- 2017-05-18 CY CY20171100525T patent/CY1118901T1/el unknown
- 2017-12-05 CY CY20171101269T patent/CY1119650T1/el unknown
2018
- 2018-03-19 CY CY2018010C patent/CY2018010I1/el unknown
- 2018-03-20 LU LU00066C patent/LUC00066I2/fr unknown
- 2018-03-20 LT LTPA2018007C patent/LTC2305817I2/lt unknown
2019
- 2019-02-25 US US16/284,316 patent/US10519231B2/en not_active Expired - Fee Related
- 2019-10-02 CY CY20191101021T patent/CY1122505T1/el unknown
- 2019-11-07 US US16/677,120 patent/US11078267B2/en not_active Expired - Lifetime
2020
- 2020-01-10 LU LU00145C patent/LUC00145I2/fr unknown
- 2020-01-13 LT LTPA2020001C patent/LTPA2020001I1/lt unknown
- 2020-01-16 CY CY2020003C patent/CY2020003I2/el unknown
- 2020-03-11 NO NO2020005C patent/NO2020005I1/no unknown

Also Published As

Publication number	Publication date
EA200300137A1 (ru)	2003-08-28
EP2305817A2 (en)	2011-04-06
KR20030034133A (ko)	2003-05-01
NO2020005I1 (no)	2020-03-11
US6902734B2 (en)	2005-06-07
NO20030614D0 (no)	2003-02-07
CY2009007I1 (el)	2012-01-25
US20170029496A1 (en)	2017-02-02
US20190248884A1 (en)	2019-08-15
NL300390I1 (en)	2009-07-01
US11078267B2 (en)	2021-08-03
US20080090290A1 (en)	2008-04-17
LUC00066I2 (el)	2018-05-25
CY1119650T1 (el)	2018-04-04
US7887807B2 (en)	2011-02-15
ES2747573T3 (es)	2020-03-10
US7279157B2 (en)	2007-10-09
US20030124123A1 (en)	2003-07-03
PT1309692E (pt)	2009-05-21
US20050196838A1 (en)	2005-09-08
YU9303A (sh)	2006-05-25
BRPI0113109B1 (pt)	2017-02-07
EP2090657A3 (en)	2011-12-28
LT2090657T (lt)	2017-07-25
NO20030614L (no)	2003-04-02
NZ535865A (en)	2007-01-26
US20130064760A1 (en)	2013-03-14
CY1122505T1 (el)	2020-05-29
US8703141B2 (en)	2014-04-22
FR09C0021I1 (el)	2009-09-25
EP3178934A1 (en)	2017-06-14
HRP20030087A2 (en)	2005-10-31
BR0113109A (pt)	2004-02-03
CY2009007I2 (el)	2012-01-25
DK2305817T3 (en)	2017-12-04
US20140178295A1 (en)	2014-06-26
NL300390I2 (en)	2010-03-01
JP2012025779A (ja)	2012-02-09
NO2011023I1 (no)	2011-10-17
EP2090657A2 (en)	2009-08-19
EP1309692B1 (en)	2009-05-13
US9676848B2 (en)	2017-06-13
US8084233B2 (en)	2011-12-27
EP3597752A1 (en)	2020-01-22
CY2020003I1 (el)	2020-05-29
US20200062841A1 (en)	2020-02-27
NZ524145A (en)	2004-11-26
JP2015061835A (ja)	2015-04-02
LU91584I2 (fr)	2009-09-10
CA2418961C (en)	2009-11-03
US10519231B2 (en)	2019-12-31
LTPA2018007I1 (lt)	2018-04-10
DK2090657T3 (en)	2017-06-06
CY2018010I2 (el)	2018-09-05
FR09C0021I2 (fr)	2010-06-11
CY2018010I1 (el)	2018-09-05
US10259867B2 (en)	2019-04-16
SI1309692T1 (sl)	2009-08-31
ES2624502T3 (es)	2017-07-14
MEP44408A (en)	2011-02-10
CN1468309A (zh)	2004-01-14
EP2305817B1 (en)	2017-09-27
ES2323760T3 (es)	2009-07-24
LT3178934T (lt)	2019-09-25
CL2009000575A1 (es)	2009-07-17
IL154325A (en)	2010-12-30
US7063964B2 (en)	2006-06-20
AU2001281137B2 (en)	2007-03-15
WO2002012500A2 (en)	2002-02-14
ME00326B (me)	2011-05-10
PT2305817T (pt)	2017-10-26
SI2090657T1 (sl)	2017-06-30
US8329171B2 (en)	2012-12-11
US20050214293A1 (en)	2005-09-29
US7166285B2 (en)	2007-01-23
CY1109149T1 (el)	2012-01-25
LTC2305817I2 (lt)	2021-04-26
HUP0302378A2 (hu)	2003-10-28
CY1118901T1 (el)	2018-02-14
ATE431412T1 (de)	2009-05-15
WO2002012500A3 (en)	2003-01-03
JP2004527212A (ja)	2004-09-09
PT2090657T (pt)	2017-05-03
IL154325A0 (en)	2003-09-17
AR030134A1 (es)	2003-08-13
JP2011173884A (ja)	2011-09-08
SI3178934T1 (sl)	2019-10-30
DK1309692T3 (da)	2009-06-15
US9409984B2 (en)	2016-08-09
LTC1309692I2 (lt)	2020-06-25
CN101550190B (zh)	2016-04-13
DK3178934T3 (da)	2019-09-30
HRP20030087B1 (en)	2012-07-31
US20050002937A1 (en)	2005-01-06
EP1309692A2 (en)	2003-05-14
NO2011023I2 (no)	2011-10-04
KR100823576B1 (ko)	2008-04-21
LTPA2020001I1 (lt)	2020-02-10
BRPI0113109B8 (pt)	2021-05-25
MY133377A (en)	2007-11-30
EP2090657B1 (en)	2017-03-01
US20050112127A1 (en)	2005-05-26
US7560247B2 (en)	2009-07-14
LUC00066I1 (el)	2018-03-23
PL360258A1 (en)	2004-09-06
HU228009B1 (en)	2012-08-28
EP3178934B1 (en)	2019-07-24
SI2305817T1 (en)	2018-02-28
MXPA03001229A (es)	2003-10-15
DE122009000025I1 (de)	2009-09-17
US20110082190A1 (en)	2011-04-07
PT3178934T (pt)	2019-10-14
CY2020003I2 (el)	2020-05-29
LU91584I9 (el)	2019-01-03
EA006673B1 (ru)	2006-02-24
RS50477B (sr)	2010-03-02
LT2305817T (lt)	2017-11-27
US20120063998A1 (en)	2012-03-15
CN101550190A (zh)	2009-10-07
JP6076303B2 (ja)	2017-02-08
LTPA2009002I1 (lt)	2020-03-25
CA2418961A1 (en)	2002-02-14
US20090274707A1 (en)	2009-11-05
LUC00145I2 (el)	2021-08-13
AU8113701A (en)	2002-02-18
US20180334500A1 (en)	2018-11-22
ES2647220T3 (es)	2017-12-20
JP4731094B2 (ja)	2011-07-20
EP2305817A3 (en)	2011-12-28
HK1135991A1 (zh)	2010-06-18
DE60138711D1 (de)	2009-06-25

Publication	Publication Date	Title
US11078267B2 (en)	2021-08-03	Method for treating lupus by administering an anti-IL-12 antibody
AU2001281137A1 (en)	2002-05-16	Anti-il-12 antibodies, compositions, methods and uses
NO333378B1 (no)	2013-05-21	Humant anti-TNF-antistoff, isolert nukleinsyremolekyl, rekombinant vektor, vertcelle og sammensetning
NO334999B1 (no)	2014-08-18	Isolert humant monoklonalt anti-dual integrin antistoff, nukleinsyremolekyl som koder for dette samt anvendelse derav for fremstilling av medikamenter.
WO2009009782A2 (en)	2009-01-15	Cynomolgus il-17 proteins, antibodies, compositions, methods and uses
ZA200301867B (en)	2004-06-25	Anti-IL-12 antibodies, compositions, methods and uses.

Legal Events

Date	Code	Title	Description
2011-10-17	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: STELARA; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU , EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004
2015-03-30	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: JANSSEN BIOTECH, US
2015-08-17	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: STELARA; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU , EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004 Extension date: 20240116
2016-09-12	SPCK	Change in the validity period of an spc	Free format text: PRODUCT NAME: STELARA- USTEKINUMAB. USTEKINIMAB ER ET HUMANT IGG1K MONOKLONALT ANTISTOFF SOM BINDES TIL P40 PROTEINSUBENHETEN TIL HUMAN CYTOKINENE IL-12 OG IL 23, PRODUSERT I EN MURIN MYELOMCELLE VED HJELP AV REKOMBINANT DNA TEKNOLOGI.; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004 Extension date: 20240120
2020-03-23	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: USTEKINUMAB. FORLENGET SPC; NAT. REG. NO/DATE: 004 20100415; FIRST REG. NO/DATE: 002 20090120 Spc suppl protection certif: 2020005 Filing date: 20200311
2021-05-03	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: USTEKINUMAB; NAT. REG. NO/DATE: 004 20100415; FIRST REG. NO/DATE: 002 20090120 Spc suppl protection certif: 2020005 Filing date: 20200311 Extension date: 20240720
2021-09-13	MK1K	Patent expired
2024-02-12	SPCX	Expiry of an spc	Spc suppl protection certif: 2011023